Established at diagnosis of a 68-year-old male with acute myeloid leukemia (AML M6) secondary to myelodysplastic syndrome (MDS, subtype refractory anemia with excess of blasts, RAEB) in 1989; Cells were described to be proliferatively responsive to GM-CSF and IL-3. Cells have been shown to synthesize haemoglobin when GM-CSF or IL-3 is substituted by erythropoietin (Epo). They have been reported to be positive for leukocyte common antigen (CD45) and some multilineage markers such as CD13, CD33 and CD34, but are negative for T- and B-cell antigens and mature myelomonocytic antigens. Due to their reaction with some monoclonal antibodies recognising erythroid and platelet glycoproteins it has been suggested that F-36P has a multilineage phenotype.

于1989年诊断1例68岁男性急性髓系白血病(AML M6)继发于骨髓增生异常综合征(MDS，亚型难治性贫血，母细胞过多，RAEB);细胞被描述为对GM-CSF和IL-3有增殖反应。细胞合成血红蛋白时GM-CSF或IL-3被红细胞生成素(Epo)取代。据报道，它们对白细胞共同抗原(CD45)和一些多系标志物如CD13、CD33和CD34呈阳性反应，但对T、b细胞抗原和成熟的髓单核细胞抗原呈阴性反应。由于其与一些识别红细胞和血小板糖蛋白的单克隆抗体的反应，已被认为F-36P具有多系表型。